Characterization of an immunologic polymorphism (D79H) in the heavy chain of factor V

Journal of Thrombosis and Haemostasis

Volumn 2, Issue 6, 2004, Pages 910-917

  van der Neut Kolfschoten, M ^a   Dirven, R J ^a   Poort, S R ^a   Van Wijk, R ^b   Vos, H L ^a   Rosendaal, F R ^a   Bertina, R M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

APC resistance; Factor V; Polymorphism; Venous thrombosis

Indexed keywords

ASPARTIC ACID; BLOOD CLOTTING FACTOR 5; HISTIDINE; MONOCLONAL ANTIBODY; PROTEIN C;

ADULT; ALLELE; AMINO ACID SUBSTITUTION; ANTIBODY AFFINITY; ARTICLE; BLOOD CLOTTING FACTOR 5 DEFICIENCY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEAVY CHAIN; HUMAN; IMMUNOLOGY; MALE; MUTATIONAL ANALYSIS; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

ACTIVATED PROTEIN C RESISTANCE; AMINO ACID SUBSTITUTION; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ANTIGENS; EXONS; FACTOR V; FACTOR V DEFICIENCY; FAMILY HEALTH; GENE FREQUENCY; GENOTYPE; HUMANS; PEDIGREE; POINT MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN SUBUNITS; VENOUS THROMBOSIS;

EID: 13244283150     PISSN: 15387933     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1538-7836.2004.00713.x     Document Type: Article

References (41)

1. Esmon CT. The subunit structure of thrombin-activated factor V. Isolation of activated factor V, separation of subunits, and reconstitution of biological activity. J Biol Chem 1979; 254: 964-73.
2. Kane WH, Majerus PW. Purification and characterization of human coagulation factor V. J Biol Chem 1981; 256: 1002-7.
3. Suzuki K, Dahlbäck B, Stenflo J. Thrombin-catalyzed activation of human coagulation factor V. J Biol Chem 1982; 257 6556-64.
4. Guinto ER, Esmon CT. Formation of a calcium-binding site on bovine activated factor V following recombination of the isolated subunits. J Biol Chem 1982; 257: 10038-43.
5. Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem 1994; 269: 31869-80.
6. Shen L, Dahlbäck B. Factor V, protein S, as synergistic cofactors to activated protein C, in degradation of factor VIIIa. J Biol Chem 1994; 269: 18735-8.
7. Varadi K, Rosing J, Tans G, Schwarz HP. Influence of factor V and factor Va on APC-induced cleavage of human factor VIII. Thromb Haemost 1995; 73: 730-1.
8. Mann KG, Kalafatis M. Factor V: a combination of Dr Jekyll and Mr Hyde. Blood 2003; 101: 20-30.
9. Nicolaes GA, Dahlbäck B. Factor V and thrombotic disease: description of a janus-faced protein. Arterioscler Thromb Vasc Biol 2002; 22: 530-8.
10. Montefusco MC, Duga S, Asselta R, Malcovati M, Peyvandi F, Santagostino E, Mannucci PM, Tenchini ML. Clinical and molecular characterization of 6 patients affected by severe deficiency of coagulation factor V. broadening of the mutational spectrum of factor V gene and in vitro analysis of the newly identified missense mutations. Blood 2003; 102: 3210-6.
11. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
12. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-7.
13. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504-8.
14. Owren PA. Parahaemophilia. haemorrhagic diathesis due to absence of a previously unknown clotting factor. Lancet 1947; 1 446-51.
15. Girolami A, Simioni P, Venturelli U, Girolami B, Zanon E. Factor V antigen levels in APC resistance, in factor V deficiency and in combined APC resistance and factor V deficiency (pseudohomozygosis for APC resistance). Blood Coagul Fibrinolysis 1997; 8: 245-8.
16. Guasch JF, Lensen RPM, Bertina RM. Molecular characterization of a type I quantitative factor V deficiency in a thrombosis patient that is 'pseudo homozygous' for activated protein C resistance. Thromb Haemost 1997; 77: 252-7.
17. Kalafatis M, Simioni P, Bernardi F. Phenotype and genotype expression in pseudohomozygous R2 factor V. Blood 2001; 98: 1988-9.
18. Lunghi B, Castoldi E, Mingozzi F, Bernardi F, Castaman G. A novel factor V null mutation detected in a thrombophilic patient with pseudo-homozygous APC resistance and in an asymptomatic unrelated subject. Blood 1998; 92: 1463-4.
19. Kalafatis M, Bernardi F, Simioni P, Lunghi B, Girolami A, Mann KG. Phenotype and genotype expression in pseudohomozygous factor VLEIDEN. the need for phenotype analysis. Arterioscler Thromb Vasc Biol 1999; 19: 336-42.
20. Castoldi E, Kalafatis M, Lunghi B, Simioni P, Ioannou PA, Petio M, Girolami A, Mann KG, Bernardi F. Molecular bases of pseudohomozygous APC resistance: the compound heterozygosity for FV R506Q and a FV null mutation results in the exclusive presence of FV Leiden molecules in plasma. Thromb Haemost 1998; 80: 403-6.
21. Guasch JF, Cannegieter S, Reitsma PH. Van't Veer-Korthof ET, Bertina RM. Severe coagulation factor V deficiency caused by a 4 bp deletion in the factor V gene. Br J Haematol 1998; 101: 32-9.
22. van Wijk R, van den Nieuwenhuis KBM, Huizinga EG, van der Meijden BB, Kraaijenhagen RJ, van Solinge WW. Five novel mutations in the gene for human blood coagulation factor V associated with type I factor V deficiency. Blood 2001; 98: 358-67.
23. Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, Shaw N, Lane CR, Lim EP, Kalyanaraman N, Nemesh J, Ziaugra L, Friedland L, Rolfe A, Warrington J, Lipshutz R, Daley GQ, Lander ES. Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet 1999; 22: 231-8.
24. Bossone A, Cappucci F, D'Andrea G, Brancaccio V, Cibelli G, Iannaccone L, Grandone E, Margaglione M. The factor V (FV) gene ASP79HIS polymorphism modulates FV plasma levels and affects the activated protein c resistance phenotype in presence of the FV Leiden mutation. Haematologica 2003; 88: 286-9.
25. Kamphuisen PW, Rosendaal FR, Eikenboom JC, Bos R, Bertina RM. Factor V antigen levels and venous thrombosis: risk profile, interaction with factor V leiden, and relation with factor VIII antigen levels. Arterioscler Thromb Vasc Biol 2000; 20: 1382-6.
26. Jenny RJ, Pittman DD, Toole JJ, Kriz RW, Aldape RA, Hewick RM, Kaufman RJ, Mann KG. Complete cDNA and derived amino acid sequence of human factor V. Proc Natl Acad Sci USA 1987; 84: 4846-50.
27. Kaufman RJ. Vectors used for expression in mammalian cells. Meth Enzymol 1990; 185: 487-511.
28. van der Neut Kolfschoten M, Dirven RJ, Vos HL, Bertina RM. The R2-haplotype associated Asp2194Gly mutation in the light chain of human factor V results in lower expression levels of FV, but has no influence on the glycosylation of Asn2181. Thromb Haemost 2003; 89: 429-37.
29. van der Neut Kolfschoten M, Dirven RJ, Tans G, Rosing J, Vos HL, Bertina RM. The activated protein C (APC) -resistant phenotype of APC cleavage site mutants of recombinant factor V in a reconstituted plasma model. Blood Coagul Fibrinolysis 2002; 13: 207-15.
30. van der Neut Kolfschoten M, Dirven RJ, Tans G, Rosing J, Vos HL, Bertina RM. Factor Va is inactivated by APC in the absence of cleavage sites at Arg306, Arg506 and Arg679. J Biol Chem 2004; 279: 6567-75.
31. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C. Leiden Thrombophilia Study. Lancet 1993; 342: 1503-6.
32. van der Meer FJ, Koster T, Vandenbroucke JP, Briet E, Rosendaal FR. The Leiden Thrombophilia Study (LETS). Thromb Haemost 1997; 78: 631-5.
33. Villoutreix BO, Dahlbäck B. Structural investigation of the A domains of human blood coagulation factor V by molecular modeling. Protein Sci 1998; 7: 1317-25.
34. Bernardi F, Faioni EM, Castoldi E, Lunghi B, Castaman G, Sacchi E, Mannucci PM. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. Blood 1997; 90: 1552-7.
35. Alhenc-Gelas M, Nicaud V, Gandrille S, van Dreden P, Amiral J, Aubry ML, Fiessinger JN, Emmerich J, Aiach M. The factor V gene A4070G mutation and the risk of venous thrombosis. Thromb Haemost 1999; 81: 193-7.
36. Faioni EM, Franchi F, Bucciarelli P, Margaglione M, De Stefano V, Castaman G, Finazzi G, Mannucci PM. Coinheritance of the HR2 haplotype in the factor V gene confers an increased risk of venous thromboembolism to carriers of factor V R506Q (factor V Leiden). Blood 1999; 94: 3062-6.
37. de Visser MC, Guasch JF, Kamphuisen PW, Vos HL, Rosendaal FR, Bertina RM. The HR2 haplotype of factor V. effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis. Thromb Haemost 2000; 83: 577-82.
38. Frischmeyer PA, Dietz HC. Nonsense-mediated mRNA decay in health and disease. Hum Mol Genet 1999; 8: 1893-900.
39. Lunghi B, Iacoviello L, Gemmati D, Dilasio MG, Castoldi E, Pinotti M, Castaman G, Redaelli R, Mariani G, Marchetti G, Bernardi F. Detection of new polymorphic markers in the factor V gene: association with factor V levels in plasma. Thromb Haemost 1996; 75: 45-8.
40. Zeibdawi AR, Grundy JE, Lasia B, Pryzdial EL. Coagulation factor Va Glu96-Asp111. A chelator-sensitive site involved in function and subunit association. Biochem J 2004; 377: 141-8.
41. Steen M, Miteva M, Villoutreix BO, Yamazaki T, Dahlbäck B, Factor V New Brunswick. Ala221Val associated with FV deficiency reproduced in vitro and functionally characterized. Blood 2003; 102: 1316-22.